Equity Overview
Price & Market Data
Price: $4.59
Daily Change: -$0.46 / 10.01%
Daily Range: $4.50 - $5.30
Market Cap: $6,888,277
Daily Volume: 51,477
Performance Metrics
1 Week: -28.68%
1 Month: -53.50%
3 Months: -34.41%
6 Months: -70.87%
1 Year: -88.02%
YTD: -71.44%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.